行情

TNXP

TNXP

Tonix
NASDAQ

实时行情|Nasdaq Last Sale

1.150
-0.040
-3.36%
盘后: 1.150 0 0.00% 17:11 12/13 EST
开盘
1.140
昨收
1.190
最高
1.180
最低
1.040
成交量
286.11万
成交额
--
52周最高
42.00
52周最低
0.8600
市值
181.15万
市盈率(TTM)
-0.0013
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

TNXP 新闻

  • Company News for Dec 13, 2019
  • Zacks.8小时前
  • Mid-Afternoon Market Update: Dow Up 200 Points; RiceBran Technologies Shares Plunge
  • Benzinga.1天前
  • Mid-Day Market Update: Crude Oil Up Over 1%; Tonix Pharmaceuticals Shares Spike Higher
  • Benzinga.1天前
  • The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win
  • Benzinga.1天前

更多

所属板块

生物技术和医学研究
-0.88%
制药与医学研究
+0.01%

热门股票

名称
价格
涨跌幅

TNXP 简况

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
展开

Webull提供Tonix Pharmaceuticals Holding Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。